Luke Sergott

Management described Signals AI and the Anthropic connector as complementary layers expanding the core Signals platform, with LabGistics to follow as a cross-workflow connector.

Max noted 4-5 month lead times with good funnel visibility. Q4 instrument performance played out as anticipated. Flattish FY26 assumption reflects continued similar CapEx environment.

Max clarified China IDx will be less than 5% of revenue in FY26. Potential oncology policy changes don't impact RVTY. Prudent assumption is management conservatism, not new fundamental risk.

Max confirmed combination: pull-forward of planned actions, reevaluation of manufacturing footprint for tariffs, and targeted IDx China sales/marketing reductions.

Max cited three dynamics: tariff headwinds, FX pressure, and specific reagent product mix headwind. Nothing structurally changed.

Max credited newborn screening outpacing birth rates through geographic and menu expansion plus Genomics England partnership expansion.

Max confirmed LRP margin targets unchanged: 25bps gross margin + 50bps SG&A leverage. Redundancy costs not meaningful enough to create headwind.

Max acknowledged conservatism, citing geopolitical/regulatory uncertainty as reason for balanced/prudent approach.

Max pinpointed summer as inflection point when restructurings normalized and lab activity picked back up.

Patrick clarified China strength is core industrial automation and pharma, not Product Inspection.

Shawn framed retail as inherently lumpy, noting US down double-digit but Europe strong with overall retail up high single-digit.

Patrick noted small exposure to academia/government/biotech mainly through liquid handling and pipettes. Pipette business slightly declining in Q4. Recovery depends on research funding; pipettes would be the indicator. Not a large part of overall business.

Shawn denied supplier cost pressure, crediting SternDrive program's digital should-costing capabilities. Explained gross margin confusion: FX 70bps headwind in Q4, acquisition mix dilutive, and Swiss tariff absorbed at 39% before reduction. Organic gross margin only down 20bps despite 190bps tariff headwind.

Shawn noted 70% of PI sold into food manufacturing which remains challenging, but mid-market innovation and portfolio expansion driving outperformance. Pipeline from Board tour encouraging for future products.

Shawn provided comprehensive 2026 segment guide: Lab low-to-mid single digit (PA outperforming), core industrial and PI both low-to-mid single digit with modest acquisition benefit, retail flat. Americas mid-single digit, Europe and China low single digit.

Shawn noted 80-90% of Western business was replacement pre-COVID. Internal data shows aging installed base. Not expected as snapback but gradual acceleration once uncertainty clears.

Shawn indicated Q4 gross margin optically similar to Q3 (volume benefit offset by tariff ramp). Year-over-year Q4 margin could be down 170-180bps from Swiss tariff impact.

Girshick attributed the implied second-half cadence to the normal lag from proposal to bookings to revenue, not a mix or demand issue; Coleman noted DSA moves from H1 organic decline to low-single-digit H2 growth.

Jim confirmed physical capacity is in good shape and headcount is well-aligned with demand. Senior scientific staff positions are filled; direct labor would be brought on a quarter ahead of need.

Jim addressed AI fears directly, calling AI an enabling technology that complements rather than disrupts preclinical work. Said NAMS are still crude and AI is early, with nothing imminent to threaten the business.

Foster said incremental hiring is essential to accommodate demand that is meaningfully above initial operating plan. Adding capacity in laboratory sciences and backfilling turnover to ensure quality and speed of execution heading into 2026.

Foster said focused on bioanalysis, geographic expansion, and in vitro/NAMs technologies. Comfortable levering to mid-to-high 2x (under 3x ceiling) given strong free cash flow that historically deleverages within 12 months.

Jim outlined drivers: AD-Detect portfolio, autoimmune testing, CardioIQ (Lp(a), ApoB, insulin resistance), consumer partnerships (WHOOP, Oura, Function Health), questhealth.com, and early innings of Elevance network wins in Nevada, Colorado, Georgia, Virginia.

Jim said January started very strong before storms hit. Systems track canceled appointments and remind patients to reschedule with nice uptick. Sam confirmed seasonality similar to 2025 and pre-COVID: Q1 weakest, Q2 strongest, step down Q3→Q4.

Jim detailed WHOOP ($199 for 65 biomarkers, 350K signups) and OURA ($99 for 50 biomarkers, 5.5M global users, 60-65% U.S.). Function Health sole lab partner. Quest direct growing 30-40% YTD.

Jim explained organic volume was down 90bps but weather/leap year accounted for 160bps headwind, implying ~70bps underlying growth. Strong March recovery and April trends in line with H2 2024.

Adam split CLS (large pharma, MSA-based, follows customer pipeline mix) from ED (smaller companies, cell/gene, rare disease). Oncology, neurology and metabolic are fastest-growing therapy areas across the business.

Adam argued Phase 2/3 trials are the last area pharma would cut. Early development is more exposed but LH is shifting mix toward mid/large pharma to reduce risk.

Adam cited Invitae overlap, LaunchPad $100-125M savings, and esoteric mix as key margin drivers for full-year expansion.

CFO clarified the innovation timeline was pulled forward, not the investment itself. Full-year margin guide raised 10bps at midpoint to 85bps expansion, incorporating Ignite structural improvements offset by inflation and Middle East logistics costs.

Padraig highlighted CTO-led portfolio refocus. Platform launches coming, accelerating in oligos/GLP-1 workflows. Software as key asymmetric investment area in ACG. Simplified structure from 20 to 9 product lines enables agile R&D allocation.